Learn how this multidisciplinary team uses the recently approved agents enasidenib, ivosidenib, midostaurin, gemtuzumab ozogamicin, and CPX-351 to provide optimal treatment for patients with acute myeloid leukemia.
In this downloadable slideset from the AML treatment update video, a team of AML experts provides their perspective on optimizing treatment choices with recently approved targeted therapies for your patients with acute myeloid leukemia.
Download this PDF team training guide for a CCO video of expert recommendations on the optimal use of recently approved targeted therapies in patients with advanced AML, including therapy selection and adverse event management.
Download this PDF of expert recommendations on the optimal management of AEs experienced with recently approved targeted therapies in patients with advanced AML.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.